Hypertrophic Cardiomyopathy Management Overview

The management of Hypertrophic Cardiomyopathy (HCM) has evolved significantly, shifting from purely symptomatic relief to a comprehensive strategy focused on sudden cardiac death (SCD) prevention and specialized interventions for outflow tract obstruction.

---

Comprehensive Management Strategy

Medical Management (First-Line)

The primary goal is to improve diastolic filling and reduce the pressure gradient across the Left Ventricular Outflow Tract (LVOT).

• Beta-Blockers: The cornerstone of therapy (e.g., Metoprolol, Atenolol). They decrease heart rate, increase diastolic filling time, and reduce ionotropic response.
• Calcium Channel Blockers: Non-dihydropyridines like Verapamil are used if beta-blockers are poorly tolerated or ineffective.
  • Caution: Avoid in patients with severe resting obstruction or heart failure.
• Disopyramide: An anti-arrhythmic with negative inotropic effects, often added to beta-blockers to further reduce LVOT gradients.
• Mavacamten: A newer, first-in-class cardiac myosin inhibitor specifically approved for symptomatic obstructive HCM.

Sudden Cardiac Death (SCD) Risk Stratification

All patients must be assessed for an Implantable Cardioverter-Defibrillator (ICD) based on:

• Prior cardiac arrest or sustained Ventricular Tachycardia (VT).
• Family history of premature HCM-related death.
• Massive left ventricular hypertrophy (wall thickness ≥ 30mm).
• Unexplained syncope.
• Apical aneurysms or low LVEF (< 50%).

---

Genetic Analysis in HCM

Genetic testing is a Class I recommendation for patients with a clinical diagnosis of HCM. It serves two primary purposes:

• Etiology Clarification: Identifying “HCM mimics” such as Fabry disease, Friedreich’s ataxia, or ATTR amyloidosis, which require entirely different treatment pathways.
• Cascade Screening: Once a pathogenic variant is found in the “proband” (the affected patient), first-degree relatives can be tested.
  • Genotype-negative relatives can generally be discharged from regular clinical surveillance.
  • Genotype-positive relatives require longitudinal monitoring (ECG/Echo) even if currently asymptomatic.
• Common Genes: Most mutations occur in the cardiac sarcomere, specifically MYH7 (Beta-myosin heavy chain) and MYBPC3 (Myosin-binding protein C).

---

Alcohol Septal Ablation

ASA is a percutaneous (non-surgical) intervention for patients with obstructive HCM who remain symptomatic despite optimal medical therapy.

The Procedure

1. Localization: A tiny amount of absolute ethanol (95-98%) is injected into a specific septal perforator artery.
2. Controlled Infarction: The alcohol causes a localized “planned myocardial infarction” of the basal septum.
3. Remodeling: The infarcted tissue thins and scars over time, widening the LVOT and reducing the pressure gradient and mitral valve systolic anterior motion (SAM).

ASA vs. Surgical Myectomy

Feature	Alcohol Septal Ablation (ASA)	Septal Myectomy (Surgery)
Invasiveness	Minimally invasive (catheter-based)	Open-heart surgery
Recovery	Shorter hospital stay	Longer recovery period
Common Risk	Permanent Pacemaker requirement (due to Heart Block)	Less risk of complete heart block
Effectiveness	Highly effective; results depend on vascular anatomy	The “Gold Standard” for long-term relief

ASA is generally preferred for older patients or those with significant comorbidities, whereas Myectomy is often favored for younger patients or those with concomitant mitral valve disease.

---